Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humalog versus insulin aspart in CSII reservoir in-use for type 1 diabetes mellitus
2017-001162-21Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human insulin and insulin aspart in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: 7-point daily mean self-monitored blood glucose on Day 6 and Hemoglobin A1c.
02
Drugs
human insulininsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-001162-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001162-21.